Bio-Connect
WB analysis of Jurkate cell lysate using GTX85278 SHOC2 antibody in (A) the absence and (B) the presence of blocking peptide. Dilution : 1 microg/ml
WB analysis of Jurkate cell lysate using GTX85278 SHOC2 antibody in (A) the absence and (B) the presence of blocking peptide. Dilution : 1 microg/ml
WB analysis of Jurkate cell lysate using GTX85278 SHOC2 antibody in (A) the absence and (B) the presence of blocking peptide. Dilution : 1 microg/ml

SHOC2 antibody

GTX85278
GeneTex
TargetSHOC2
Product group Antibodies
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    GeneTex
  • Product Name
    SHOC2 antibody
  • Delivery Days Customer
    9
  • Application Supplier Note
    WB: 1 - 2 microg/mL. IHC-P: 5 microg/mL. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
  • Concentration
    1 mg/ml
  • Formulation
    Liquid
  • Gene ID8036
  • Target name
    SHOC2
  • Target description
    SHOC2 leucine rich repeat scaffold protein
  • Target synonyms
    leucine-rich repeat protein SHOC-2; NSLH1; SIAA0862; SOC2; soc-2 suppressor of clear homolog; SUR8
  • Protein IDQ9UQ13
  • Protein Name
    Leucine-rich repeat protein SHOC-2
  • Scientific Description
    SHOC2 protein participates in protein binding / transferase activity in the fibroblast growth factor receptor signaling pathway and Ras protein signal transduction. It is a widely expressed protein composed almost entirely of leucine-rich repeats (LRR), with a lysine-rich sequence at the amino terminus and cytoplasmically localized. SHOC2 acts as a positive modulator of the RAS-MAPK signaling cascade, which is elicited by EGL-15 and LET-23 and mediated by LET-60. SHOC2 together with protein phosphatase 1c (PP1c) forms a highly specific M-Ras effector complex and is essential for activation of the MAPK pathway by growth factors. Furthermore, in tumor cells with Ras gene mutations, inhibition of SHOC2 expression inhibits MAPK, but not PI3K activity. The SHOC2-PP1c holoenzyme provides an attractive therapeutic target for inhibition of the MAPK pathway in cancer. Recent studies show that aberrantly acquired N-myristoylation of SHOC2 causes human disease Noonan-like syndrome with loose anagen hair.
  • Storage Instruction
    -20°C or -80°C,2°C to 8°C
  • UNSPSC
    12352203